li001

Researchers have discovered a new way to make immunotherapy work against pancreatic cancer by targeting so-called cryptic peptides. These peptides come from parts of DNA that normally do not make proteins, sometimes called the “dark genome.” Cancer cells, however, often use these regions, creating abnormal peptides that do not appear in healthy tissue. The researchers […]

Researchers at Rockefeller University have uncovered how T cells switch from rest to attack, revealing a previously hidden motion in T cell receptors that helps explain how the immune system recognizes and responds to cancer. Using advanced cryo-electron microscopy, the team found that the T cell receptor normally stays tightly closed and inactive. When it

The FLAIL-C Phase 2 trial tested whether combining anti-PD-1 immunotherapy with the tyrosine kinase inhibitor anlotinib could improve outcomes for patients with advanced, unresectable chondrosarcoma. Seventy patients participated, including 32 with dedifferentiated chondrosarcoma, 8 with Grade III conventional disease, and 30 with Grade II disease. Patients received either anlotinib alone or the combination therapy, with